What Defines Sapropterin Non-Response?
Sapropterin (Kuvan), used to lower blood phenylalanine (Phe) in phenylketonuria (PKU), shows response in about 20-30% of patients—a drop of at least 30% in Phe after a 4-week trial. Non-response occurs when Phe stays elevated despite treatment, often due to specific genetic or metabolic factors.[1]
Key Genetic Biomarkers for Non-Response
Mutations in the PAH gene predict non-response:
- Null mutations (e.g., splicing defects like IVS12+1G>A, large deletions, or nonsense mutations like R408W): These abolish enzyme activity, blocking sapropterin's cofactor role. Patients with two null alleles rarely respond.[2][3]
- BH4-loading test failures: No Phe reduction (>30%) during a BH4 challenge flags non-responders; correlates 80-90% with sapropterin outcomes.[4]
- Compound heterozygotes: One severe mutation paired with a milder one reduces response odds to under 20%.[2]
Metabolic and Biochemical Markers
- Baseline Phe >1,000 μmol/L: Higher levels predict poorer response; cutoffs above 600-1,200 μmol/L show <10% response rates.[1][5]
- High pterin levels or abnormal pterin profiles: Excess neopterin or low sepiapterin indicates defects in BH4 synthesis/recycling, incompatible with sapropterin.[3]
- Dihydropteridine reductase (DHPR) deficiency: Low DHPR activity prevents BH4 regeneration, marking non-responders.[4]
How Clinicians Test for These
A 4-week sapropterin challenge (20 mg/kg/day) confirms response empirically. Genetic panels (e.g., PAH sequencing) and BH4 loading tests guide predictions—95% accuracy for null genotypes. Non-responders shift to low-Phe diets or enzyme substitution like pegvaliase.[1][6]
Why Do These Biomarkers Matter?
They avoid futile trials, cutting costs (sapropterin ~$100K/year) and delays. Response genotype databases (e.g., BIO-PKU) score mutations by predicted responsiveness.[2]
Sources
[1]: FDA Label for Kuvan
[2]: Muntau et al., Mol Genet Metab 2013
[3]: Blau et al., J Inherit Metab Dis 2010
[4]: Vockley et al., Mol Genet Metab 2014
[5]: Burton et al., Pediatrics 2007
[6]: DrugPatentWatch.com - Sapropterin Patents